The DCAT Pulse: The Tariff Outlook & Pharma

Evolving US tariff policy is a key variable in the cost structures, manufacturing strategies, and supply chains of bio/pharma companies and their suppliers. A DCAT webinar gives an executive briefing on what is crucial to consider in supply planning amid tariff uncertainty.

Evolving US tariff/trade policy is top of mind for the bio/pharma industry and is a key variable in the cost structures, manufacturing strategies, and supply chains of bio/pharmaceutical companies and their suppliers. Unpacking what tariffs are in place, and what additional tariffs may come to be and how they will be implemented is a challenge unto itself, but an even greater challenge is how can companies put forth effective supply plans amid such tariff uncertainty?

To address that critical question, a DCAT webinar, The Tariff Outlook & Pharma, airing January 22, 2026 (10:00-10:30 AM EST-US), brings together leading industry experts on what may lie ahead in 2026 and what is important to consider in effective supply planning. Jens Charlieson, Head of Transport & Trade Compliance at Swedish Orphan Biovitrum AB (Sobi), and Gabriela de Almeida, Managing Director and Partner at Boston Consulting Group, will share key insights on the crucial factors and scenarios to consider for effective supply planning and trade compliance.

The webinar is part of The DCAT Pulse, a new, member-focused insights hub from the Drug, Chemical & Associated Technologies Association (DCAT) that brings together fresh perspectives and seasoned expertise, spotlighting trends and opportunities that help DCAT Member Companies stay informed, engaged, and ahead of the curve in a dynamic marketplace.

The webinar, The Tariff Outlook & Pharma, was developed by the volunteer DCAT Supply Management Committee, composed of senior to mid-level executives involved in sourcing, procurement and supply management. The webinar is provided exclusively and complimentary to all employees of DCAT Member Companies, who can register here. Not able to attend the webinar on January 22? No problem. The webinar will be available for on-demand viewing, but you must register to view.

Recent Feature Articles

FDA Begins Pilot To Incentivize US-Based Pharma Manufacturing

By
FDA has selected seven companies to participate in the agency’s PreCheck Pilot Program, a new initiative designed to incentivize US-based pharma manufacturing and facilitate operational readiness of greenfield facilities. Which companies were selected, and what does the program entail?

Mid-Year Review: What’s Trending in New Drug Approvals?

By
FDA’s Center for Drug Evaluation and Research has approved 24 new drugs thus far in 2026. Which companies and drug candidates have crossed the finish line, and how is the product mix between small molecules and biologics faring?

New CEO Takes the Helm of Takeda: What’s Next?

By
In a planned succession, Julie Kim took the helm at Takeda as President and CEO with former President and CEO Christophe Weber stepping down following a 12-year tenure. The company faces a transitional period as it seeks to return to growth. What’s the plan?
Wave

The State of the State: Continuous Manufacturing

By
FDA’s Emerging Technology Program, a collaborative program between the agency and industry, aims to facilitate bio/pharma companies’ adoption of new manufacturing technologies, including continuous manufacturing. Where do things stand?